Oregon Dermatology and Research Center   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Portland OR United States (1989)

Organization Overview

First Clinical Trial
2007
NCT00453271
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Oregon Dermatology & Research Center

Active Ingredients

Drugs in Phase 3 Trials (3)

betamethasone (celestone) (1 trial)

calcipotriene (dovonex) (1 trial)

cd07805/47 (2 trials)

Drugs in Phase 2 Trials (1)

nb-002 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Erythema (Phase 3)

Onychomycosis (Phase 2)

Psoriasis (Phase 3)

Rosacea (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4